Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 1/20 | 0.41 |
| ▸ | CBX7 | O95931 | 1/20 | 0.34 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.34 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.34 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913134 | 0.88 | SSTR5 (0.42) | SSTR5GRIN2BHPGDSALDH1A1DYRK1A | |
| SCHEMBL10073866 | 0.88 | SSTR5 (0.43) | SSTR5ALDH1A1DYRK1ARXFP1PDE10A | |
| SCHEMBL13794680 | 0.88 | SSTR5 (0.43) | SSTR5ALDH1A1DYRK1ARXFP1PDE10A | |
| SCHEMBL10074047 | 0.87 | SSTR5 (0.42) | SSTR5ALDH1A1DYRK1ARXFP1PTGER4 | |
| SCHEMBL10073869 | 0.87 | DYRK1A (0.36) | CBX7CDYL2CDYLCDY1; CDY1BDYRK1A | |
| SCHEMBL5001501 | 0.86 | SSTR5 (0.41) | SSTR5ALDH1A1DYRK1ARXFP1PDE10A | |
| SCHEMBL13901109 | 0.85 | SSTR5 (0.40) | SSTR5HPGDSALDH1A1DYRK1ARXFP1 | |
| SCHEMBL14094058 | 0.84 | SSTR5 (0.41) | SSTR5GRIN2BALDH1A1DYRK1ARXFP1 | |
| SCHEMBL14094056 | 0.84 | SSTR5 (0.40) | SSTR5HPGDSALDH1A1DYRK1APDE10A | |
| SCHEMBL10074048 | 0.84 | SSTR5 (0.40) | SSTR5GRIN2BALDH1A1TRPV1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562909-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK SHARP & DOHME (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | SSTR5 1031/4885CBX7 3087/4885CDYL2 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.